• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向肝 X 受体治疗非酒精性脂肪性肝病。

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease.

机构信息

College of Pharmacy, Sookmyung Women's University, Seoul 04310, Republic of Korea.

Drug Information Research Institute, Sookmyung Women's University, Seoul 04310, Republic of Korea.

出版信息

Cells. 2023 May 1;12(9):1292. doi: 10.3390/cells12091292.

DOI:10.3390/cells12091292
PMID:37174692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10177243/
Abstract

Non-alcoholic fatty liver disease (NAFLD) refers to a range of conditions in which excess lipids accumulate in the liver, possibly leading to serious hepatic manifestations such as steatohepatitis, fibrosis/cirrhosis and cancer. Despite its increasing prevalence and significant impact on liver disease-associated mortality worldwide, no medication has been approved for the treatment of NAFLD yet. Liver X receptors α/β (LXRα and LXRβ) are lipid-activated nuclear receptors that serve as master regulators of lipid homeostasis and play pivotal roles in controlling various metabolic processes, including lipid metabolism, inflammation and immune response. Of note, NAFLD progression is characterized by increased accumulation of triglycerides and cholesterol, hepatic de novo lipogenesis, mitochondrial dysfunction and augmented inflammation, all of which are highly attributed to dysregulated LXR signaling. Thus, targeting LXRs may provide promising strategies for the treatment of NAFLD. However, emerging evidence has revealed that modulating the activity of LXRs has various metabolic consequences, as the main functions of LXRs can distinctively vary in a cell type-dependent manner. Therefore, understanding how LXRs in the liver integrate various signaling pathways and regulate metabolic homeostasis from a cellular perspective using recent advances in research may provide new insights into therapeutic strategies for NAFLD and associated metabolic diseases.

摘要

非酒精性脂肪性肝病(NAFLD)是指一系列肝脏内脂质蓄积过多的病症,可能导致严重的肝脏表现,如脂肪性肝炎、纤维化/肝硬化和肝癌。尽管其在全球范围内的患病率不断增加,并对与肝病相关的死亡率有重大影响,但目前尚无药物被批准用于治疗 NAFLD。肝 X 受体 α/β(LXRα 和 LXRβ)是脂激活的核受体,作为脂质稳态的主要调节剂,在控制包括脂质代谢、炎症和免疫反应在内的各种代谢过程中发挥关键作用。值得注意的是,NAFLD 的进展特征是甘油三酯和胆固醇的积累增加、肝脏从头合成脂质、线粒体功能障碍和炎症加剧,所有这些都高度归因于 LXR 信号的失调。因此,针对 LXR 可能为治疗 NAFLD 提供有前景的策略。然而,新出现的证据表明,调节 LXR 的活性具有各种代谢后果,因为 LXR 的主要功能在细胞类型依赖性方面明显不同。因此,从细胞角度理解肝脏中的 LXR 如何整合各种信号通路并调节代谢稳态,利用研究中的最新进展,可能为 NAFLD 和相关代谢性疾病的治疗策略提供新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bce/10177243/b430df544c26/cells-12-01292-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bce/10177243/c52e14e0bf9a/cells-12-01292-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bce/10177243/b430df544c26/cells-12-01292-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bce/10177243/c52e14e0bf9a/cells-12-01292-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bce/10177243/b430df544c26/cells-12-01292-g002.jpg

相似文献

1
Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease.靶向肝 X 受体治疗非酒精性脂肪性肝病。
Cells. 2023 May 1;12(9):1292. doi: 10.3390/cells12091292.
2
Liver X receptors bridge hepatic lipid metabolism and inflammation.肝 X 受体连接肝脏脂质代谢和炎症。
J Dig Dis. 2012 Feb;13(2):69-74. doi: 10.1111/j.1751-2980.2011.00554.x.
3
Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells.肝 X 受体调节肝非实质细胞中的胆固醇代谢和免疫。
Int J Mol Sci. 2019 Oct 11;20(20):5045. doi: 10.3390/ijms20205045.
4
Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.阿坎酸通过 FXR/LXRs 依赖性途径调节非酒精性脂肪性肝病中的脂肪生成。
Chem Biol Interact. 2019 Sep 25;311:108794. doi: 10.1016/j.cbi.2019.108794. Epub 2019 Aug 14.
5
Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中肝 X 受体的生物学机制及相关天然调节剂。
Biomed Pharmacother. 2019 May;113:108778. doi: 10.1016/j.biopha.2019.108778. Epub 2019 Mar 18.
6
Nuclear receptors and nonalcoholic fatty liver disease.核受体与非酒精性脂肪性肝病
Biochim Biophys Acta. 2016 Sep;1859(9):1083-1099. doi: 10.1016/j.bbagrm.2016.03.002. Epub 2016 Mar 4.
7
Inhibition of LXR signaling by SULT2B1b promotes liver regeneration after partial hepatectomy in mouse models of nonalcoholic fatty liver disease.磺基转移酶 2B1b 通过抑制 LXR 信号通路促进非酒精性脂肪性肝病小鼠模型肝部分切除术后的肝脏再生。
Am J Physiol Gastrointest Liver Physiol. 2020 Jul 1;319(1):G87-G96. doi: 10.1152/ajpgi.00380.2019. Epub 2020 Jun 1.
8
Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.芝麻素通过肝X受体α(LXRα)和过氧化物酶体增殖物激活受体α(PPARα)改善高脂饮食大鼠的肝脏脂肪变性和炎症。
Nutr Res. 2016 Sep;36(9):1022-1030. doi: 10.1016/j.nutres.2016.06.015. Epub 2016 Jun 27.
9
The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease.核受体在非酒精性脂肪性肝病发病机制和治疗中的作用。
Int J Biol Sci. 2024 Jan 1;20(1):113-126. doi: 10.7150/ijbs.87305. eCollection 2024.
10
Ursolic Acid, a Novel Liver X Receptor α (LXRα) Antagonist Inhibiting Ligand-Induced Nonalcoholic Fatty Liver and Drug-Induced Lipogenesis.熊果酸,一种新型肝 X 受体α(LXRα)拮抗剂,抑制配体诱导的非酒精性脂肪肝和药物诱导的脂肪生成。
J Agric Food Chem. 2018 Nov 7;66(44):11647-11662. doi: 10.1021/acs.jafc.8b04116. Epub 2018 Oct 25.

引用本文的文献

1
Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions.代谢、炎症和肿瘤疾病中的核受体:作用机制、治疗进展及未来方向
Eur J Med Res. 2025 Sep 9;30(1):843. doi: 10.1186/s40001-025-03073-6.
2
Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease.释放治疗潜力:探索新兴核受体之间的相互作用以对抗脂肪性肝病中的代谢功能障碍。
NPJ Metab Health Dis. 2024 Jul 3;2(1):13. doi: 10.1038/s44324-024-00013-6.
3
Intestinal Activation of LXRα Counteracts Metabolic-Associated Steatohepatitis Features in Mice.

本文引用的文献

1
The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD.氧化应激和核受体在非酒精性脂肪性肝病发生发展中的作用及机制
Oxid Med Cell Longev. 2021 Oct 27;2021:6889533. doi: 10.1155/2021/6889533. eCollection 2021.
2
New targets for NAFLD.非酒精性脂肪性肝病的新靶点
JHEP Rep. 2021 Aug 8;3(6):100346. doi: 10.1016/j.jhepr.2021.100346. eCollection 2021 Dec.
3
Mechanisms and disease consequences of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的机制及疾病后果
肠道中肝X受体α的激活可对抗小鼠代谢相关脂肪性肝炎的特征。
Nutrients. 2025 Apr 15;17(8):1349. doi: 10.3390/nu17081349.
4
Integrated liver-secreted and plasma proteomics identify a predictive model that stratifies MASH.整合肝脏分泌蛋白质组学和血浆蛋白质组学鉴定出一种对非酒精性脂肪性肝炎进行分层的预测模型。
Cell Rep Med. 2025 May 20;6(5):102085. doi: 10.1016/j.xcrm.2025.102085. Epub 2025 Apr 17.
5
Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target.非酒精性脂肪性肝病的未来治疗前景:聚焦核受体,一个有前景的治疗靶点。
Med Pharm Rep. 2024 Apr;97(2):111-119. doi: 10.15386/mpr-2628. Epub 2024 Apr 25.
6
Onion Polyphenols as Multi-Target-Directed Ligands in MASLD: A Preliminary Molecular Docking Study.洋葱多酚作为非酒精性脂肪性肝病的多靶点导向配体:初步分子对接研究
Nutrients. 2024 Apr 20;16(8):1226. doi: 10.3390/nu16081226.
7
Targeting nuclear receptors for NASH/MASH: From bench to bedside.针对非酒精性脂肪性肝炎/代谢相关脂肪性肝炎的核受体:从 bench 到 bedside。 (注:bench可理解为实验室研究阶段,bedside可理解为临床应用阶段 ,这里直接保留英文未完全意译,因为准确翻译这两个词在该语境下较难找到完全对应的精准中文表述,直接保留英文更能体现原文专业语境)
Liver Res. 2024 Mar;8(1):34-45. doi: 10.1016/j.livres.2024.03.002.
Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.
4
Liver X receptors and liver physiology.肝脏X受体与肝脏生理学
Biochim Biophys Acta Mol Basis Dis. 2021 Jun 1;1867(6):166121. doi: 10.1016/j.bbadis.2021.166121. Epub 2021 Mar 11.
5
4β-Hydroxycholesterol is a prolipogenic factor that promotes SREBP1c expression and activity through the liver X receptor.4β-羟基胆固醇是一种促前体生成因子,通过肝 X 受体促进 SREBP1c 的表达和活性。
J Lipid Res. 2021;62:100051. doi: 10.1016/j.jlr.2021.100051. Epub 2021 Feb 23.
6
Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH.通过脂质感应核受体 PPARs、FXR 和 LXR 对 NASH 中代谢途径的转录调控。
Cell Mol Gastroenterol Hepatol. 2021;11(5):1519-1539. doi: 10.1016/j.jcmgh.2021.01.012. Epub 2021 Feb 2.
7
Cholesterol Metabolites 25-Hydroxycholesterol and 25-Hydroxycholesterol 3-Sulfate Are Potent Paired Regulators: From Discovery to Clinical Usage.胆固醇代谢物25-羟基胆固醇和25-羟基胆固醇3-硫酸酯是强效配对调节剂:从发现到临床应用。
Metabolites. 2020 Dec 25;11(1):9. doi: 10.3390/metabo11010009.
8
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.非酒精性脂肪性肝炎:过氧化物酶体增殖物激活受体的作用。
Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):24-39. doi: 10.1038/s41575-020-00366-5. Epub 2020 Oct 22.
9
Screening for liver X receptor modulators: Where are we and for what use?筛选肝 X 受体调节剂:我们在哪里,用于什么用途?
Br J Pharmacol. 2021 Aug;178(16):3277-3293. doi: 10.1111/bph.15286. Epub 2020 Dec 7.
10
Liver X Receptor Alpha Activation Inhibits Autophagy and Lipophagy in Hepatocytes by Dysregulating Autophagy-Related 4B Cysteine Peptidase and Rab-8B, Reducing Mitochondrial Fuel Oxidation.肝 X 受体α的激活通过扰乱自噬相关 4B 半胱氨酸肽酶和 Rab-8B 抑制肝细胞中的自噬和脂噬,减少线粒体燃料氧化。
Hepatology. 2021 Apr;73(4):1307-1326. doi: 10.1002/hep.31423. Epub 2021 Mar 16.